首页> 外文期刊>Experimental Eye Research >Human pluripotent stem cell-derived limbal epithelial stem cells on bioengineered matrices for corneal reconstruction
【24h】

Human pluripotent stem cell-derived limbal epithelial stem cells on bioengineered matrices for corneal reconstruction

机译:人类多能干细胞衍生的角膜缘上皮干细胞在生物工程基质上重建角膜

获取原文
获取原文并翻译 | 示例
           

摘要

Corneal epithelium is renewed by limbal epithelial stem cells (LESCs), a type of tissue-specific stem cells located in the limbal palisades of Vogt at the corneo-scleral junction. Acute trauma or inflammatory disorders of the ocular surface can destroy these stem cells, leading to limbal stem cell deficiency (LSCD) - a painful and vision-threatening condition. Treating these disorders is often challenging and complex, especially in bilateral cases with extensive damage. Human pluripotent stem cells (hPSCs) provide new opportunities for corneal reconstruction using cell-based therapy. Here, we investigated the use of hPSC-derived LESC-like cells on bioengineered collagen matrices in serum-free conditions, aiming for clinical applications to reconstruct the corneal epithelium and partially replace the damaged stroma. Differentiation of hPSCs towards LESC-like cells was directed using small-molecule induction followed by maturation in corneal epithelium culture medium. After four to five weeks of culture, differentiated cells were seeded onto bioengineered matrices fabricated as transparent membranes of uniform thickness, using medical-grade porcine collagen type I and a hybrid cross-linking technology. The bioengineered matrices were fully transparent, with high water content and swelling capacity, and parallel lamellar microstructure. Cell proliferation of hPSC-LESCs was significantly higher on bioengineered matrices than on collagen-coated control wells after two weeks of culture, and LESC markers p63 and cytokeratin 15, along with proliferation marker Ki67 were expressed even after 30 days in culture. Overall, hPSC-LESCs retained their capacity to self-renew and proliferate, but were also able to terminally differentiate upon stimulation, as suggested by protein expression of cytokeratins 3 and 12. We propose the use of bioengineered collagen matrices as carriers for the clinically-relevant hPSC-derived LESC-like cells, as a novel tissue engineering approach for corneal reconstruction. (C) 2015 Elsevier Ltd. All rights reserved.
机译:角膜上皮由角膜缘上皮干细胞(LESCs)更新,这是一种组织特异性干细胞,位于角膜-巩膜交界处Vogt的角膜缘。眼表的急性外伤或炎症性疾病会破坏这些干细胞,导致角膜缘干细胞缺乏症(LSCD)-一种痛苦且威胁视力的疾病。这些疾病的治疗通常具有挑战性和复杂性,尤其是在双边损害严重的情况下。人类多能干细胞(hPSC)使用基于细胞的疗法为角膜重建提供了新的机会。在这里,我们研究了在无血清条件下在生物工程化胶原蛋白基质上使用hPSC衍生的LESC样细胞,旨在临床应用来重建角膜上皮并部分替代受损的基质。使用小分子诱导,然后在角膜上皮培养基中成熟,指导hPSC向LESC样细胞的分化。培养四到五周后,使用医学级I型猪胶原蛋白和杂交交联技术,将分化的细胞播种到生物工程基质上,该基质被制成均匀厚度的透明膜。生物工程基质是完全透明的,具有高水含量和溶胀能力,并且具有平行的层状微结构。培养两周后,在生物工程基质上,hPSC-LESCs的细胞增殖明显高于胶原包被的对照孔,甚至在培养30天后,仍表达LESC标记p63和细胞角蛋白15以及增殖标记Ki67。总体而言,hPSC-LESC保留了自我更新和增殖的能力,但也能够在刺激后最终分化,如细胞角蛋白3和12的蛋白表达所暗示。我们建议使用生物工程胶原蛋白基质作为临床上的载体相关的hPSC来源的LESC样细胞,作为一种新颖的组织工程方法进行角膜重建。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号